We are live on ! Find out more
TBRA

Tobira Therapeutics, Inc. Common Stock
TBRA

Delisted

TBRA was delisted on the 31st of October, 2016.

42 hedge funds and large institutions have $103M invested in Tobira Therapeutics, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,668% more capital invested

Capital invested by funds: $5.8M → $103M (+$96.7M)

217% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 6

31% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 13

11% more funds holding

Funds holding: 3842 (+4)

Holders
42
Holders Change
+4
Holders Change %
+10.53%
% of All Funds
1.13%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.08%
New
17
Increased
19
Reduced
6
Closed
13
Calls
$405K
Puts
Net Calls
+$405K
Net Calls Change
+$379K
Name Holding Trade Value Shares
Change
Change in
Stake
TA
26
Teachers Advisors
New York
$65K +$20.6K +1,409 +60%
BCM
27
Blume Capital Management
California
$59K +$49.7K +3,400 New
New York State Common Retirement Fund
28
New York State Common Retirement Fund
New York
$38K +$32.2K +2,200 New
AIG
29
American International Group
New York
$24.3K +$4.85K +332 +31%
NFA
30
Nationwide Fund Advisors
Ohio
$22K -$15 -1 -0.1%
BA
31
BlackRock Advisors
Delaware
$21K +$7.6K +520 +72%
Citigroup
32
Citigroup
New York
$18K +$13.2K +904 +962%
TRCT
33
Tower Research Capital (TRC)
New York
$13K +$11.3K +774 New
SO
34
STRS Ohio
Ohio
$9K -$15 -1 -0.2%
Bank of America
35
Bank of America
North Carolina
$8K +$6.32K +432 +10,800%
Invesco
36
Invesco
Georgia
$5K +$4.25K +291 New
UBS Group
37
UBS Group
Switzerland
$3K +$2.44K +167 New
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$3K +$2.73K +187 New
Wells Fargo
39
Wells Fargo
California
$2K +$366 +25 +26%
Barclays
40
Barclays
United Kingdom
$1K -$58 -4 -8%
LTFS
41
Ladenburg Thalmann Financial Services
Florida
$1K -$15 -1 -2%
PNC Financial Services Group
42
PNC Financial Services Group
Pennsylvania
$1K +$307 +21 +47%
PAM
43
Panagora Asset Management
Massachusetts
-$509K -46,343 Closed
Geode Capital Management
44
Geode Capital Management
Massachusetts
-$133K -12,196 Closed
Bank of New York Mellon
45
Bank of New York Mellon
New York
-$78K -7,128 Closed
California Public Employees Retirement System
46
California Public Employees Retirement System
California
-$43K -4,344 Closed
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
-$50.3K -3,438 Closed
VKH
48
Virtu KCG Holdings
New York
-$28K -2,544 Closed
D.E. Shaw & Co
49
D.E. Shaw & Co
New York
-$25K -2,248 Closed
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
-$22K -2,048 Closed

TBRA Hedge Fund Activity: Q2 2015 in Review

42 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Tobira Therapeutics, Inc. Common Stock (TBRA) for Q2 2015, worth a combined $103M — up 1,668% from $5.8M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new TBRA positions and 13 closed out — a net gain of 4 holders — while 19 added to existing stakes and 6 trimmed.

The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $39.4M. The largest seller was Panagora Asset Management, exiting entirely with an estimated $509K sold.

  • 42 institutional investors held Tobira Therapeutics, Inc. Common Stock (TBRA) as of Q2 2015, up from 38 in Q1 2015.
  • Funds reported $103M of Tobira Therapeutics, Inc. Common Stock stock for Q2 2015, up 1,668% quarter-over-quarter.
  • 17 funds opened new Tobira Therapeutics, Inc. Common Stock positions in Q2 2015 and 13 closed out, a net change of +4 holders.
  • The largest Tobira Therapeutics, Inc. Common Stock buyer in Q2 2015 was Novo Holdings A/S, an estimated $39.4M added.
  • The largest Tobira Therapeutics, Inc. Common Stock seller in Q2 2015 was Panagora Asset Management, an estimated $509K sold.

Based on aggregated 13F filings for Q2 2015.